The pharmaceutical industry trade group hopes to convince you that it is not all bark and no bite.

In response to the outcry over Marathon Pharmaceuticals, which plans to sell a decades-old drug for $89,000 and also maintain a monopoly, the Pharmaceutical Research and Manufacturers of America slammed the company for “actions [that] are not consistent with the mission of our organization.” And the group promised a “comprehensive review” of its membership criteria.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!